Welcome to our dedicated page for Atai Beckley SEC filings (Ticker: ATAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AtaiBeckley Inc. filings document a clinical-stage biotechnology issuer with Nasdaq-listed common shares and psychiatry-focused investigational drug programs. The company’s regulatory record includes proxy and governance disclosures, shareholder voting matters, operating and financial results, clinical and regulatory updates, and risk-related information tied to development programs such as BPL-003, VLS-01, and EMP-01.
Material-event filings and registration-related documents also cover capital-structure activity, public offering agreements, resale registration matters, and acquisition-related share registration connected with Beckley Psytech. Historical filings under ATAI Life Sciences N.V. and Atai Beckley N.V. provide reference for the company’s corporate transition, financing activity, governance framework, and formal disclosure of business updates.
atai Life Sciences N.V. (Nasdaq: ATAI) filed an 8-K announcing two material developments:
1. $50 million PIPE financing: On 1 July 2025 the company signed Subscription Agreements with several investors—including Apeiron Investment Group, the family office of co-founder Christian Angermayer—to sell 18,264,840 ordinary shares at $2.19 and issue a pre-funded warrant for 4,566,210 shares at a $0.01 exercise price (also priced at $2.19 per underlying share). Closing is targeted for Q3-25 and is subject to customary conditions, notably expiration of the Hart-Scott-Rodino waiting period related to Apeiron’s participation. Either side may terminate if the deal is not completed by 1 Nov 2025. Securities are being sold under Section 4(a)(2) and will be registered for resale under a new Registration Rights Agreement. Management expects the additional capital to extend the company’s cash, short-term securities and public equity runway into H2-2027.
2. Positive Phase IIb data for BPL-003 in treatment-resistant depression (TRD): Beckley Psytech—currently subject to an acquisition agreement with ATAI—reported that a single 12 mg intranasal dose of BPL-003 produced a mean 11.1-point reduction in MADRS versus 5.8 for the 0.3 mg comparator (p = 0.0038) at Day 29. The 8 mg dose yielded a 12.1-point reduction (p = 0.0025). Statistically significant effects emerged by Day 2 and remained durable through Day 57. Safety was acceptable, with >99% of adverse events mild or moderate and no suicide-related signals. The company plans to advance the 8 mg dose to Phase III.
- Use of proceeds: working capital and advancement of ATAI’s clinical pipeline; funds will not be used to finance the pending Beckley acquisition.
- Placement agents: TD Securities, Leerink Partners, Guggenheim Securities and Berenberg.
- Dilution impact: Potential issuance of ~22.8 million new shares (inclusive of warrant) before registration.
Overall, the financing strengthens ATAI’s balance sheet while positive clinical data from its pending target bolsters the strategic rationale for the Beckley acquisition.
atai Life Sciences N.V. (Nasdaq: ATAI) filed an 8-K announcing two material developments:
1. $50 million PIPE financing: On 1 July 2025 the company signed Subscription Agreements with several investors—including Apeiron Investment Group, the family office of co-founder Christian Angermayer—to sell 18,264,840 ordinary shares at $2.19 and issue a pre-funded warrant for 4,566,210 shares at a $0.01 exercise price (also priced at $2.19 per underlying share). Closing is targeted for Q3-25 and is subject to customary conditions, notably expiration of the Hart-Scott-Rodino waiting period related to Apeiron’s participation. Either side may terminate if the deal is not completed by 1 Nov 2025. Securities are being sold under Section 4(a)(2) and will be registered for resale under a new Registration Rights Agreement. Management expects the additional capital to extend the company’s cash, short-term securities and public equity runway into H2-2027.
2. Positive Phase IIb data for BPL-003 in treatment-resistant depression (TRD): Beckley Psytech—currently subject to an acquisition agreement with ATAI—reported that a single 12 mg intranasal dose of BPL-003 produced a mean 11.1-point reduction in MADRS versus 5.8 for the 0.3 mg comparator (p = 0.0038) at Day 29. The 8 mg dose yielded a 12.1-point reduction (p = 0.0025). Statistically significant effects emerged by Day 2 and remained durable through Day 57. Safety was acceptable, with >99% of adverse events mild or moderate and no suicide-related signals. The company plans to advance the 8 mg dose to Phase III.
- Use of proceeds: working capital and advancement of ATAI’s clinical pipeline; funds will not be used to finance the pending Beckley acquisition.
- Placement agents: TD Securities, Leerink Partners, Guggenheim Securities and Berenberg.
- Dilution impact: Potential issuance of ~22.8 million new shares (inclusive of warrant) before registration.
Overall, the financing strengthens ATAI’s balance sheet while positive clinical data from its pending target bolsters the strategic rationale for the Beckley acquisition.
Form 4 overview: ATAI Life Sciences N.V. filed a Form 4 on 27 June 2025 detailing a new option grant to director Andrea Heslin Smiley.
The award covers 103,000 options on ATAI common shares at an exercise price of $2.25, granted 26 June 2025. The option vests on the earlier of (i) the day before ATAI’s next annual shareholder meeting or (ii) 26 June 2026, and expires 26 June 2035. No common shares were acquired or disposed; the transaction only increases the director’s derivative holdings.
Following the grant, Smiley directly owns 103,000 derivative securities and no change is reported in non-derivative share ownership. The filing appears to be routine director compensation, carries no indication of a Rule 10b5-1 trading plan, and provides limited insight into ATAI’s operational or financial performance.
ATAI Life Sciences N.V. – Key details from Form 4
Director Amir H. Kalali filed a Form 4 on 27 June 2025 reporting the grant of a non-derivative stock option covering 103,000 common shares of ATAI Life Sciences N.V. The option was issued on 26 June 2025 with an exercise price of $2.25 per share and will vest on the earlier of (i) the day before ATAI’s next annual meeting or (ii) 26 June 2026. The option expires on 26 June 2035. After the transaction, Kalali holds 103,000 derivative securities directly. No open-market purchases or sales of ATAI shares were reported in this filing.
The filing represents a routine equity incentive award designed to align the director’s long-term interests with shareholders. Because the option is not yet exercised, there is no immediate change to share count or insider ownership of outstanding common shares.
ATAI Life Sciences N.V. (ATAI) – Form 4 insider filing
Director Sabrina Martucci Johnson reported the grant of 103,000 stock options on 26 June 2025. The options carry a strike price of $2.25 and expire on 26 June 2035. Vesting occurs on the earlier of the day before ATAI’s next annual meeting or 26 June 2026. Following this transaction Ms. Johnson beneficially owns 103,000 derivative securities, held directly. No non-derivative share transactions were disclosed.
The filing was signed by attorney-in-fact Ryan Barrett on 27 June 2025. No 10b5-1 trading plan box was checked, and the director remains subject to Section 16 reporting obligations.
ATAI Life Sciences N.V. (ATAI) Form 4 highlights: on June 26, 2025 director John Francis Hoffman was granted a stock option covering 206,000 common shares at an exercise price of $2.25 per share.
The option vests 33% on June 26, 2026; the remaining 67% vests in 24 equal monthly installments, reaching full vesting on June 26, 2028. After the award, Hoffman beneficially owns 206,000 derivative securities; no non-derivative share transactions were reported.
The filing, signed by attorney-in-fact Ryan Barrett on June 27, 2025, reflects routine director compensation and does not disclose any sales or purchases of existing shares.